278 related articles for article (PubMed ID: 17409392)
1. Targeting multiple arms of the apoptotic regulatory machinery.
Dai Y; Grant S
Cancer Res; 2007 Apr; 67(7):2908-11. PubMed ID: 17409392
[TBL] [Abstract][Full Text] [Related]
2. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
3. Restoring cancer's death sentence.
Letai A
Cancer Cell; 2006 Nov; 10(5):343-5. PubMed ID: 17097553
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.
Konopleva M; Contractor R; Tsao T; Samudio I; Ruvolo PP; Kitada S; Deng X; Zhai D; Shi YX; Sneed T; Verhaegen M; Soengas M; Ruvolo VR; McQueen T; Schober WD; Watt JC; Jiffar T; Ling X; Marini FC; Harris D; Dietrich M; Estrov Z; McCubrey J; May WS; Reed JC; Andreeff M
Cancer Cell; 2006 Nov; 10(5):375-88. PubMed ID: 17097560
[TBL] [Abstract][Full Text] [Related]
5. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.
Sun JG; Xiang J; Zeng XL; Li X; Wu P; Fung KP; Liu FY
Cancer Lett; 2014 Dec; 355(2):253-63. PubMed ID: 25304383
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.
Tagscherer KE; Fassl A; Campos B; Farhadi M; Kraemer A; Böck BC; Macher-Goeppinger S; Radlwimmer B; Wiestler OD; Herold-Mende C; Roth W
Oncogene; 2008 Nov; 27(52):6646-56. PubMed ID: 18663354
[TBL] [Abstract][Full Text] [Related]
7. Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad.
Yin S; Dong Y; Li J; Fan L; Wang L; Lu J; Vang O; Hu H
Apoptosis; 2012 Apr; 17(4):388-99. PubMed ID: 22179721
[TBL] [Abstract][Full Text] [Related]
8. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
van Delft MF; Wei AH; Mason KD; Vandenberg CJ; Chen L; Czabotar PE; Willis SN; Scott CL; Day CL; Cory S; Adams JM; Roberts AW; Huang DC
Cancer Cell; 2006 Nov; 10(5):389-99. PubMed ID: 17097561
[TBL] [Abstract][Full Text] [Related]
9. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
[TBL] [Abstract][Full Text] [Related]
11. Regulation of stress-induced nuclear protein redistribution: a new function of Bax and Bak uncoupled from Bcl-x(L).
Lindenboim L; Blacher E; Borner C; Stein R
Cell Death Differ; 2010 Feb; 17(2):346-59. PubMed ID: 19816507
[TBL] [Abstract][Full Text] [Related]
12. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
[TBL] [Abstract][Full Text] [Related]
14. The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics.
Karlberg M; Ekoff M; Huang DC; Mustonen P; Harvima IT; Nilsson G
J Immunol; 2010 Aug; 185(4):2555-62. PubMed ID: 20639495
[TBL] [Abstract][Full Text] [Related]
15. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
High LM; Szymanska B; Wilczynska-Kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB
Mol Pharmacol; 2010 Mar; 77(3):483-94. PubMed ID: 20038611
[TBL] [Abstract][Full Text] [Related]
16. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
[TBL] [Abstract][Full Text] [Related]
17. Subversion of the Bcl-2 life/death switch in cancer development and therapy.
Adams JM; Huang DC; Strasser A; Willis S; Chen L; Wei A; van Delft M; Fletcher JI; Puthalakath H; Kuroda J; Michalak EM; Kelly PN; Bouillet P; Villunger A; O'Reilly L; Bath ML; Smith DP; Egle A; Harris AW; Hinds M; Colman P; Cory S
Cold Spring Harb Symp Quant Biol; 2005; 70():469-77. PubMed ID: 16869785
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis.
Rudner J; Elsaesser SJ; Müller AC; Belka C; Jendrossek V
Biochem Pharmacol; 2010 Jan; 79(1):10-20. PubMed ID: 19665451
[TBL] [Abstract][Full Text] [Related]
19. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
20. Killing cancer cells by flipping the Bcl-2/Bax switch.
Cory S; Adams JM
Cancer Cell; 2005 Jul; 8(1):5-6. PubMed ID: 16023593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
